View Older Stories View More Recent Stories
-
Roth Capital Upgrades Ligand Pharma (LGND) to Buy
-
Roth Capital Downgrades Ligand Pharma (LGND) to Neutral Citing Valuation
-
Ligand Pharma (LGND) PT Raised to $172 at Roth Capital
-
Roth Capital Reiterates Buy on Ligand Pharma (LGND)
-
Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Presentation of New Phase 2 DUET Data (RTRX)
-
Roth Capital Trims PT on Ligand Pharma (LGND) to $150 Amid New Kyprolis Data (AMGN)
-
Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Initiation of LGD-6972 Phase 2 in T2D
-
Streetinsider.com's Hot Lunchtime Reads 9/7: (AMD) (LGND) (EXPR) (GILD)
-
Roth Capital Bumps PT on Ligand Pharma (LGND) up to $151 Following Sparsentan Data; Affirms at 'Buy'
-
Roth Capital Positive on Ligand Pharma (LGND) Ahead of Sept. Catalysts; Affirms at 'Buy'
-
Streetinsider.com's Hot Lunchtime Reads 8/5: (MU) (MRK) (LGND) (FIVE)
-
Roth Capital Says to Buy Ligand Pharma (LGND) on Today's 'Bad' Downgrade
-
Roth Capital Bumps PT on Ligand Pharma (LGND) up to $149; Says Running on All Cylinders
-
Roth Capital Affirms Ligand Pharma (LGND) Following Solid Q2 Revenue Results for Promacta (NVS)
-
Roth Affirms Ligand Pharma (LGND) at 'Buy' Following Strong Severe PPD Data from SAGE Therapeutics (SAGE)
-
Roth Positive on Ligand Pharma (LGND) Amid Another Key OmniAb Collaboration (GILD)
-
Roth Keeps Ligand Pharma (LGND) at 'Buy' as Kyprolis Receives Expanded Indication in Europe (AMGN)
-
Streetinsider.com's Hot Lunchtime Reads 5/12: (AAPL) (BA) (LVLT) (JCP)
-
Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' as Baxdela Phase 3 Met Primary Endpoints
-
Roth Affirms Ligand Pharma (LGND) at 'Buy' Following FDA Acceptance of Lundbeck's CE-Carbamazepine NDA Resubmission
-
Orphan Drug Exclusivity for Spectrum's (SPPI) Evomela is Important Increment for Ligand (LGND) - Roth Capital
-
Roth Remains Bullish on Ligand Pharma (LGND) as Revolade Gets Expanded Approval in Europe (NVS)
-
Roth Bumps PT on Ligand Pharma (LGND) up to $147 Following Evomela Approval
-
Roth Reiterates Ligand Pharma (LGND) at 'Buy' Following Additional Kyprolis Approval
-
Streetinsider.com's Hot Lunchtime Reads 1/13: (ESRX) (MSFT) (AAPL) (LGND)
-
Roth Capital Impressed by Speed of Ligand (LGND) Capitalizing on OMT Acquisition; Affirms at 'Buy'
-
Roth Capital Remains Bullish Following Ligand Pharma's (LGND) Supply Agreement with Gilead (GILD)
-
Roth Positive on Ligand's (LGND) Move to Acquire OMT; Bumps PT to $146
-
New PDUFA Date, Licensing Agreement Bode Well for Ligand Pharma (LGND); Roth Affirms at 'Buy'
-
Ligand Pharma (LGND) Provides Updates at Analyst Day; Roth Capital Raises Price Target to $144
-
Ligand Pharma (LGND) Announces FDA CRL for Evomela's NDA; Roth Capital Reiterates Buy
-
Roth Capital Trims PT on Ligand (LGND) to $138; Will Remove Evomela from Revenue Projections (SPPI)
-
Roth Capital Raises Price Target on Ligand Pharma (LGND) Ahead of 3Q Results
-
Roth Capital Reiterates Buy on Ligand Pharma (LGND) Following E.U. Approval of Promacta
-
Ligand Pharma (LGND) Reaffirmed at 'Buy' by Roth Following European Promacta Approval, Evomela Update
-
Roth Capital Highlights Biotech Picks 'for the Turn' and Over the Long Haul (PTN) (LGND) (TGTX) (CLDX)
-
Streetinsider.com's Hot Lunchtime Reads 8/24: (AAPL) (LGND) (MON) (FCAU)
-
Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Expanded Promacta Indication
-
Ligand Pharma (LGND) Becomes 'Value Play' as Viking (VKTX) Advances VK2809 - Roth Capital
-
Roth Capital Remains Bullish on Ligand Pharma (LGND) Following FDA Approval of Kyprolis sNDA (AMGN)
-
Roth Affirms Ligand Pharma (LGND) at 'Buy'; Promacta Q2 Revenue Outpaces Expectations (NVS)
-
Promacta Receives FDA Approval for Children with ITP; Roth Raffirms Ligan Pharma (LGND) at 'Buy' (NVS)
-
Roth Capital 'Impressed' with '6972 Safety Profile; Affirms Ligand Pharma (LGND) at 'Buy'
-
Roth Capital Raised Price Target Following Ligand Pharma (LGND) Receipt of Milestone Payment
-
Roth Capital Affirms Ligand Pharma (LGND) Following Positive SAGE-547 Update (SAGE)
-
Streetinsider.com's Hot Lunchtime Reads 5/11: (LGND) (AAPL) (RL) (JPM) (OIL)
-
Ligand Pharma (LGND) PT Lifted to $127 at Roth Capital Following Q1 and as Pipeline Expands
-
Roth Affirms Ligand (LGND) at 'Buy' Following Amgen (AMGN), Spectrum (SPPI) Updates
-
Roth Capital Positive on Ligand Pharma (LGND); Kyprolis Met Primary Endpoint in ENDEAVOR Trial (AMGN)
-
Ligand's (LGND) License with Sermonix Demonstrates Great Example of Core Business Model - Roth Capital

